US law firms’ secret deal weapon blunted as Pfizer pulls plug on $160bn inversion bid

The wave of ‘inversion’ bids into Europe from US companies could be set to end, with the strategy pioneered by Skadden, Arps, Slate, Meagher & Flom hit this week as US drug maker Pfizer terminated its $160bn deal to acquire Allergan amid US tax reforms.

This article is for Legal Business subscribers. Please log in or subscribe to read on.

Related Content

City reacts to a ‘pedestrian’ Budget

Weil in numbers: the remaining partner bench

Trading Places: Sidley continues funds and finance build while Milbank grows its new Chicago office

Ropes makes up four London partners in first City promotions since 2023

Latham makes up 36 partners, with none outside US and EU

US firms lead as LSEG acquires Octus from Permira for $3.5bn

‘There’s a lot of money in Chicago’ – the city’s top lawyers on what’s driving business in the Midwest

Legal 500 US: Latham tops the charts in new US rankings

Revolving Doors: Travers and Shearman exodus continues as US firms pick up the talent